Advanced Medical Optics to Present at the 2005 Merrill Lynch Pharmaceutical, Biotechnology and Medical Device Conference

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Advanced Oncotherapy Plc	LSE:AVO	London	Ordinary Share	GB00BD6SX109	ORD 25P

Share Name

Share Symbol

Market

Type

Share ISIN

Share Description

Advanced Oncotherapy Plc

LSE:AVO

London

Ordinary Share

GB00BD6SX109

ORD 25P

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

1.925

0.00

01:00:00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Medical Laboratories	0	-29.49M	-0.0549	-0.35	10.32M

Industry Sector

Turnover

Profit

EPS - Basic

PE Ratio

Market Cap

Medical Laboratories

-29.49M

-0.0549

-0.35

10.32M

Advanced Medical Optics to Present at the 2005 Merrill Lynch Pharmaceutical, Biotechnology and Medical Device Conference

02/02/2005 12:30pm

PR Newswire (US)

Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more Advanced Oncotherapy Charts.

Advanced Medical Optics to Present at the 2005 Merrill Lynch Pharmaceutical, Biotechnology and Medical Device Conference Advanced Medical Optics, Inc. (AMO) [NYSE: AVO], a global leader in ophthalmic surgical devices and eye care products, today announced that Executive Vice President of Operations and Finance and Chief Financial Officer Richard A. Meier will present an overview of the company at the 2005 Merrill Lynch Pharmaceutical, Biotechnology and Medical Device Conference in New York on Wednesday, February 9, 2005, at 1:15 p.m. ET. To access an audio webcast of the presentation via the internet, please visit AMO's Investors/Media site at http://www.amo-inc.com/. About Advanced Medical Optics Advanced Medical Optics, Inc. (AMO) is a global leader in the development, manufacturing and marketing of ophthalmic surgical and contact lens care products. The company focuses on developing a broad suite of innovative technologies and devices to address a wide range of eye disorders. Products in the ophthalmic surgical line include foldable intraocular lenses, phacoemulsification systems, viscoelastics and related products used in cataract and refractive surgery, and microkeratomes used in LASIK procedures for refractive error correction. AMO owns or has the rights to such well- known ophthalmic surgical product brands as Phacoflex(R), Clariflex(R), Array(R), Sensar(R), Tecnis(R), CeeOn(R) and Verisyse(R) intraocular lenses, the Sovereign(R) and Sovereign(R) CompactTM phacoemulsification systems with WhiteStar(TM) technology, the Healon(R) family of viscoelastics, the Baerveldt(R) glaucoma shunt and the Amadeus(TM) microkeratome. Products in the contact lens care line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting drops. Among the well-known contact lens care product brands the company possesses are COMPLETE(R), COMPLETE(R) Blink-N-Clean(R), COMPLETE(R) Moisture PLUS(TM), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R) and blink(TM) branded products. Amadeus is a licensed product of, and a trademark of SIS, Ltd. Advanced Medical Optics, Inc. is based in Santa Ana, California, and employs approximately 2,800 worldwide. The company has direct operations in about 20 countries and markets products in approximately 60 countries. For more information, visit http://www.amo-inc.com/. Investor Contact: Erika Richmond (714) 247-8348 DATASOURCE: Advanced Medical Optics CONTACT: Erika Richmond,+1-714-247-8348, of Advanced Medical Optics Web site: http://www.amo-inc.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AVO Advanced Oncotherapy Plc